Telix Pharmaceuticals Ltd
TLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002007191
In the last 90 days, Telix Pharmaceuticals Ltd insiders filed 1 open-market purchase and 0 sales; 62 institutions reported holding it in 13F filings for Q2 2026, worth $36.6M in total; no superinvestor holds it.
Other share classesTLPPF
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Telix Pharmaceuticals Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $20.0K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$20.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Telix Pharmaceuticals Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Smith Darren Charlton | Group Chief Financial Officer | 13,992 | Sep 14, 2026 | 2 |
| Behrenbruch Christian | MD & Group CEO | 20,742,935Indirect | May 6, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 (view filing)7:20 PM ET | Sep 7 | 7 daysLate | Smith Darren CharltonGroup Chief Financial Officer | PPurchase | +2.07K | $9.66 | +$20.0K | +17.4%14.0K after | |
| May 6, 2026 (view filing) | Apr 28-29 | 8 daysLate | Behrenbruch ChristianMD & Group CEO | PPurchase | +67.9K | $14.67 | +$996.7K | +0.3%20.7M after | 2 lots |